Chronic myelogenous leukemia (CML) is a type of cancer that starts in hematopoietic progenitors in the bone marrow. CML is caused by a genetic aberration occurring in an early hematopoietic cell forming an abnormal gene called BCR-ABL, which turns the cell into a CML cell.
A landmark in CML clinical research, indeed a milestone in cancer therapy at large, was the development of remarkably efficacious tyrosine kinase inhibitors (TKIs) that target BCR-ABL which have been established as the standard treatment for CML, leading to dramatic improvements in patient outcomes. Advances in CML treatment with the use of TKIs mandate regular updating of concepts and management and, for this reason, the European LeukemiaNet recently updated recommendations for 1st line of treatment, monitoring of response to treatment by molecular and cytogenetic techniques, including definitions for optimal or suboptimal response or even failure.
The CMLab-GR project concerns the establishment of a lab network for clinicobiological data of CML patients from major hematology centers in Greece with the following objectives:
- To provide a unified platform with molecular data of CML patients in order to correlate clinical and laboratory data from different medical centers and laboratories
- To develop an efficient management system with integration and validation mechanisms and thus eliminating data inconsistency and redundancy and improving data mining, data sharing and statistical analysis
- To study the evolution of molecular results overtime in relation to treatment
A relational database system is available through online web forms only to authorized and certified users for the registration of retrospective and prospective data.